Founded
2020
CEO
Richard Francis
Founders
Prof. Moin Saleem
Prof. Mauro Giacca
% Shareholding
84%
Stage
Pre-clinical
Raised in a Series A in November 2020
£45m

Unless stated all financials at 31 March 2022

Purespring website

Purespring seeks to advance gene therapies for the treatment of chronic renal diseases that are currently poorly addressed with existing treatments.

Purespring is one of the first AAV gene therapy companies focused on the kidney globally and will seek to treat a number of debilitating chronic diseases that are currently poorly addressed with existing therapies. It has been founded around the seminal work of Professor Moin Saleem, Head of Bristol Renal where he heads a world leading group researching glomerular diseases.

Purespring has also established an in-vivo functional screening platform, FunSel, to initially screen for protective factors that could have applications across several kidney diseases. FunSel has been developed by Professor Mauro Giacca, a leader in gene therapy of cardiovascular disorders, and provides Purespring with a target discovery platform uniquely suited to systematically move gene therapy beyond monogenic disorders.

Investment thesis

  • A number of chronic kidney diseases are poorly addressed by existing therapies, which are primarily based around the lowering of blood pressure and often progressing to dialysis and kidney transplantation.
  • Purespring is developing disease modifying therapies for a number of monogenic and non-monogenic kidney diseases

Key risks

  • Highly innovative concept in emerging space
  • Clinical risk by addressing non-monogenic disorders

Key risks are Syncona team view

The Purespring Therapeutics pipeline

Research Pre-clinical Clinical
  • Undisclosed programme

Syncona team

Chris Hollowood

Chris Hollowood

Chris is the Chief Investment Officer of Syncona Investment Management Ltd. He has been instrumental in the foundation and development of Syncona's gene therapy strategy, where it has founded companies focused on the eye, the liver, the kidney, and central nervous system. He is Chairman of Freeline, SwanBio and Purespring and was also previously Chairman of retinal gene therapies Nightstar, which…
View Chris' biography
Position
Chair
Qualification
PhD
Michael Kyriakides

Michael Kyriakides

Michael Kyriakides is an Investment Partner of Syncona Investment Management Ltd. He works closely with Syncona portfolio companies Freeline Therapeutics, Purespring Therapeutics and Clade Therapeutics.  Previously, Michael was a member of the Life Sciences team at L.E.K. Consulting, where he worked in projects for pharmaceutical, biotech and private equity clients. Prior to joining L.E.K. Consult…
View Michael's biography
Position
Board member
Qualification
PhD
Alice Renard

Alice Renard

Alice is an Investment Partner of Syncona Investment Management Ltd. She is also currently Head of Operations at Purespring Therapeutics and works closely with Anaveon. Alice serves as an Observer on the Board of Purespring and Anaveon. Prior to joining Syncona, Alice was an Investment Banking Analyst within Barclays’ Healthcare Corporate Finance and M&A team, where she worked on transactions…
View Alice's biography
Qualification
PhD

Purespring Therapeutics leaders and founders

Richard Francis

Richard Francis

Chief Executive Officer
Moin Saleem

Moin Saleem

Founder

Other gene therapy portfolio companies